K. Mattson

9.8k total citations · 3 hit papers
178 papers, 7.5k citations indexed

About

K. Mattson is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, K. Mattson has authored 178 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Pulmonary and Respiratory Medicine, 72 papers in Oncology and 28 papers in Molecular Biology. Recurrent topics in K. Mattson's work include Lung Cancer Treatments and Mutations (58 papers), Lung Cancer Research Studies (52 papers) and Occupational and environmental lung diseases (47 papers). K. Mattson is often cited by papers focused on Lung Cancer Treatments and Mutations (58 papers), Lung Cancer Research Studies (52 papers) and Occupational and environmental lung diseases (47 papers). K. Mattson collaborates with scholars based in Finland, United States and Netherlands. K. Mattson's co-authors include Rodryg Ramlau, L. Tammilehto, Joachim von Pawel, Frances A. Shepherd, Ronald L. Burkes, J. Bérille, Janet Dancey, Susan Coughlin, Yong Kim and Nathan Levitan and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

K. Mattson

174 papers receiving 7.2k citations

Hit Papers

Prospective Randomized Trial of Docetaxel Versus Best Sup... 2000 2026 2008 2017 2000 2003 2000 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
    2000 1.7k citations Frances A. Shepherd, Janet Dancey et al. Journal of Clinical Oncology profile →
  2. Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
    2003 763 citations K. Mattson, Rodryg Ramlau et al. Journal of Clinical Oncology profile →
  3. Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
    2000 606 citations U. Gatzemeier, K. Mattson et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Mattson Finland 38 5.6k 4.2k 1.5k 673 419 178 7.5k
Mark Vincent Canada 38 3.7k 0.7× 3.8k 0.9× 1.5k 1.0× 723 1.1× 656 1.6× 171 6.5k
Philip Bonomi United States 42 4.4k 0.8× 4.9k 1.2× 2.1k 1.4× 978 1.5× 648 1.5× 241 8.0k
Stephen L. Graziano United States 39 2.9k 0.5× 2.8k 0.7× 1.3k 0.8× 695 1.0× 459 1.1× 117 5.2k
Hiroshi Ueoka Japan 37 3.7k 0.7× 4.2k 1.0× 1.7k 1.2× 501 0.7× 377 0.9× 212 6.5k
Nagio Takigawa Japan 41 2.9k 0.5× 2.9k 0.7× 1.9k 1.3× 749 1.1× 360 0.9× 304 5.2k
Anne S. Tsao United States 42 4.3k 0.8× 2.6k 0.6× 1.4k 0.9× 724 1.1× 436 1.0× 217 6.7k
Gregory A. Masters United States 36 4.0k 0.7× 4.1k 1.0× 1.3k 0.9× 841 1.2× 395 0.9× 127 6.9k
Alessandro Morabito Italy 40 3.4k 0.6× 4.8k 1.1× 1.7k 1.1× 1.7k 2.5× 443 1.1× 217 7.2k
Gérard Zalcman France 39 3.0k 0.5× 3.5k 0.8× 2.1k 1.4× 890 1.3× 539 1.3× 299 6.7k
Daniel Betticher Switzerland 38 2.2k 0.4× 2.4k 0.6× 1.7k 1.1× 850 1.3× 402 1.0× 154 5.5k

Countries citing papers authored by K. Mattson

Since Specialization
Citations

This map shows the geographic impact of K. Mattson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Mattson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Mattson more than expected).

Fields of papers citing papers by K. Mattson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Mattson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Mattson. The network helps show where K. Mattson may publish in the future.

Co-authorship network of co-authors of K. Mattson

This figure shows the co-authorship network connecting the top 25 collaborators of K. Mattson. A scholar is included among the top collaborators of K. Mattson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Mattson. K. Mattson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Scagliotti, Giorgio V., Aleksandra Szczęsna, Rodryg Ramlau, et al.. (2006). Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer. British Journal of Cancer. 94(10). 1375–1382. 25 indexed citations
2.
3.
4.
5.
Kettunen, Eeva, Tiina Ollikainen, M. Taavitsainen, et al.. (2001). Gene expression profiling of malignant mesothelioma cell lines: cDNA array study. International Journal of Cancer. 91(4). 492–496. 2 indexed citations
6.
Kettunen, Eeva, Tiina Ollikainen, M. Taavitsainen, et al.. (2001). Gene expression profiling of malignant mesothelioma cell lines: cDNA array study. International Journal of Cancer. 91(4). 492–496. 50 indexed citations
7.
Shepherd, Frances A., Janet Dancey, Rodryg Ramlau, et al.. (2000). Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy. Journal of Clinical Oncology. 18(10). 2095–2103. 1717 indexed citations breakdown →
8.
Halme, Maija, Mikko Hallman, Tarja Ruotsalainen, et al.. (1999). Tumour response and radiation-induced lung injury in patients with recurrent small cell lung cancer treated with radiotherapy and concomitant interferon-α. Lung Cancer. 23(1). 39–52. 4 indexed citations
9.
Tammilehto, L., Stig Nordling, Marja‐Leena Nurminen, et al.. (1998). Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. British Journal of Cancer. 77(2). 260–269. 80 indexed citations
10.
Chevalier, Thierry Le, Maya Gottfried, U. Gatzemeier, et al.. (1997). Etude multicentrique de phase II de la gemcitabine dans les cancers bronchiques non à petites cellules (CBNPC). Bulletin du Cancer. 84(3). 282–288. 1 indexed citations
11.
Klášterský, Jean, M.H. Cullen, David Ball, et al.. (1997). Concurrent treatments and induction treatments for unresectable tumors. Lung Cancer. 17. S27–S28. 2 indexed citations
12.
Tammilehto, L., et al.. (1996). High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines. British Journal of Cancer. 74(10). 1534–1540. 25 indexed citations
13.
Kinnula, Vuokko L., Petra Pietarinen-Runtti, Kari O. Raivio, et al.. (1996). Manganese superoxide dismutase in human pleural mesothelioma cell lines. Free Radical Biology and Medicine. 21(4). 527–532. 42 indexed citations
14.
Metcalf, Robert A., Judith A. Welsh, W P Bennett, et al.. (1992). p53 and Kirsten-ras mutations in human mesothelioma cell lines.. PubMed. 52(9). 2610–5. 118 indexed citations
15.
Mäkelä, Tomi P., K. Mattson, & Kari Alitalo. (1991). Tumour markers and oncogenes in lung cancer. European Journal of Cancer and Clinical Oncology. 27(10). 1323–1327. 8 indexed citations
16.
Kinnula, Vuokko L., K. Mattson, & Kari Cantell. (1989). Pharmacokinetics and Toxicity of Inhaled Human Interferon-α in Patients with Lung Cancer. Journal of Interferon Research. 9(4). 419–423. 28 indexed citations
17.
Tiainen, Marianne, L. Tammilehto, J. Rautonen, et al.. (1989). Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma. British Journal of Cancer. 60(4). 618–626. 73 indexed citations
18.
Kinnula, Vuokko L., K. Mattson, & K Cantell. (1989). PHARMACOKINETICS AND TOXICITY OF INHALED HUMAN INTERFERON-ALPHA IN PATIENTS WITH LUNG-CANCER. Journal of Interferon & Cytokine Research. 9(4). 419–423. 10 indexed citations
19.
Mattson, K., et al.. (1980). Accuracy of determination of doubling time in lung cancer. Europe PMC (PubMed Central). 4. 49–49. 2 indexed citations
20.
Mattson, K., et al.. (1980). Clinical experience with cefamandole in pneumonia.. PubMed. suppl 25. 103–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark Vincent Breakdown of academic impact, for papers by Philip Bonomi Breakdown of academic impact, for papers by Stephen L. Graziano Breakdown of academic impact, for papers by Hiroshi Ueoka Breakdown of academic impact, for papers by Nagio Takigawa Breakdown of academic impact, for papers by Anne S. Tsao Breakdown of academic impact, for papers by Gregory A. Masters Breakdown of academic impact, for papers by Alessandro Morabito Breakdown of academic impact, for papers by Gérard Zalcman Breakdown of academic impact, for papers by Daniel Betticher
Rankless by CCL
2026